Free Trial

Zevra Therapeutics (ZVRA) Competitors

Zevra Therapeutics logo
$10.61 -0.07 (-0.66%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$10.60 -0.01 (-0.09%)
As of 10/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZVRA vs. CPRX, ARQT, IBRX, APGE, TVTX, DNLI, OGN, IDYA, AGIO, and DYN

Should you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Catalyst Pharmaceuticals (CPRX), Arcutis Biotherapeutics (ARQT), ImmunityBio (IBRX), Apogee Therapeutics (APGE), Travere Therapeutics (TVTX), Denali Therapeutics (DNLI), Organon & Co. (OGN), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry.

Zevra Therapeutics vs. Its Competitors

Zevra Therapeutics (NASDAQ:ZVRA) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Zevra Therapeutics presently has a consensus target price of $24.00, indicating a potential upside of 126.20%. Catalyst Pharmaceuticals has a consensus target price of $33.20, indicating a potential upside of 58.40%. Given Zevra Therapeutics' higher possible upside, research analysts plainly believe Zevra Therapeutics is more favorable than Catalyst Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zevra Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Catalyst Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00

Catalyst Pharmaceuticals has a net margin of 37.36% compared to Zevra Therapeutics' net margin of 4.33%. Catalyst Pharmaceuticals' return on equity of 40.78% beat Zevra Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Zevra Therapeutics4.33% -112.40% -37.67%
Catalyst Pharmaceuticals 37.36%40.78%35.36%

In the previous week, Catalyst Pharmaceuticals had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 8 mentions for Catalyst Pharmaceuticals and 6 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 1.12 beat Catalyst Pharmaceuticals' score of 0.90 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zevra Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Catalyst Pharmaceuticals
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Catalyst Pharmaceuticals has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zevra Therapeutics$62.02M9.60-$105.51M-$0.21-50.52
Catalyst Pharmaceuticals$558.50M4.59$163.89M$1.6512.70

Zevra Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Summary

Catalyst Pharmaceuticals beats Zevra Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Zevra Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZVRA vs. The Competition

MetricZevra TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$595.59M$3.02B$6.24B$10.67B
Dividend YieldN/A57.75%5.72%4.81%
P/E Ratio-50.5227.5331.1930.71
Price / Sales9.60613.11560.36173.93
Price / CashN/A168.3237.0861.44
Price / Book14.345.6512.056.61
Net Income-$105.51M$33.06M$3.33B$277.10M
7 Day Performance-1.85%3.16%1.93%2.56%
1 Month Performance11.45%8.14%7.77%3.77%
1 Year Performance36.90%-2.49%56.40%33.01%

Zevra Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZVRA
Zevra Therapeutics
2.8704 of 5 stars
$10.61
-0.7%
$24.00
+126.2%
+34.3%$595.59M$62.02M-50.5220Gap Down
CPRX
Catalyst Pharmaceuticals
4.8424 of 5 stars
$20.55
+0.1%
$33.20
+61.6%
-2.1%$2.51B$491.73M12.4580News Coverage
Analyst Forecast
ARQT
Arcutis Biotherapeutics
1.1261 of 5 stars
$20.88
-0.1%
$19.80
-5.2%
+139.1%$2.51B$196.54M-27.84150News Coverage
Upcoming Earnings
IBRX
ImmunityBio
3.0757 of 5 stars
$2.40
-5.1%
$10.75
+347.9%
-41.3%$2.49B$14.74M-5.00590Positive News
Gap Up
APGE
Apogee Therapeutics
2.9846 of 5 stars
$55.15
+3.3%
$92.63
+68.0%
+2.6%$2.46BN/A-13.3591Analyst Forecast
TVTX
Travere Therapeutics
2.6918 of 5 stars
$27.32
-0.7%
$35.21
+28.9%
+55.1%$2.45B$233.18M-13.39460News Coverage
Upcoming Earnings
Analyst Forecast
DNLI
Denali Therapeutics
4.1766 of 5 stars
$16.66
-0.4%
$33.50
+101.1%
-39.6%$2.44B$330.53M-5.95430Analyst Forecast
OGN
Organon & Co.
4.9145 of 5 stars
$9.28
-1.1%
$17.33
+86.8%
-46.8%$2.44B$6.40B3.454,000News Coverage
Positive News
Upcoming Earnings
Analyst Forecast
IDYA
IDEAYA Biosciences
4.3231 of 5 stars
$29.26
+5.7%
$43.36
+48.2%
-0.1%$2.43B$7M-7.7280Analyst Forecast
Analyst Revision
High Trading Volume
AGIO
Agios Pharmaceuticals
4.2543 of 5 stars
$42.33
+2.0%
$57.25
+35.2%
-3.9%$2.41B$36.50M3.85390Upcoming Earnings
Analyst Forecast
DYN
Dyne Therapeutics
2.7319 of 5 stars
$16.38
-0.2%
$34.07
+108.0%
-45.0%$2.34BN/A-4.24100Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ZVRA) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners